erdafitinib-releasing intravesical system tar-210
Generic: Erdafitinib-releasing Intravesical System TAR-210
erdafitinib-releasing intravesical system tar-210: 1 clinical trial tracked.
erdafitinib-releasing intravesical system tar-210 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about erdafitinib-releasing intravesical system tar-210, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trials (1)
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
Primary endpoint: Disease-free Survival (DFS)
InterventionalRandomizedopen220 targetStarted 2025-09Completion 2032-0350 sites · Argentina, Belgium, Brazil, China…Janssen Research & Development, LLC